Director/PDMR Shareholding
Updated : 15:58
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director/PDMR Shareholding
The Company was notified on 8 December 2020 that Wild Indigo SA ("Wild Indigo"), a company of which Manuel Llobet, Chief Executive Officer, has indirect interests, transferred 3,125,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") to Mr Llobet for estate planning purposes. The transfer of Ordinary Shares represents approximately 94 per cent. of Mr Llobet's entire holding in the Company.
Mr Llobet is a Director and PDMR and Wild Indigo is deemed to be a person closely associated with Mr Llobet under Article 19 of the EU Market Abuse Regulation 596/2014.
Following the transfer of shares, Mr Llobet's holding of Ordinary Shares remains unchanged at a total of 3,325,000 Ordinary Shares, representing 0.52% of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Manuel Llobet | ||||
2 | Reason for the notification | |||||
|
| Chief Executive Officer, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Allergy Therapeutics plc | ||||
b) | LEI | 213800PQ7AHK7KGVOE23 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | 0.1p ordinary shares
GB00B02LCQ05 | ||||
b) | Nature of the transaction
| Transfer of shares from Wild Indigo to Manuel Llobet (direct interests) | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
N/A
N/A
| ||||
e) | Date of the transaction
| 8 December 2020 | ||||
f) | Place of the transaction
| London Stock Exchange - AIM | ||||
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.